ArticleBMC cancer2022

ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial.

Elizabeth Smyth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.